Navigation Links
Insmed Initiates Clinical Study for Follow-on Biologic Version of Neupogen(R)
Date:4/16/2008

INS-19 Receives Regulatory Clearance

RICHMOND, Va., April 16 /PRNewswire-FirstCall/ -- Insmed Inc. (Nasdaq: INSM), a developer of follow-on biologics and biopharmaceuticals, today announced that it has received approval from the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) to initiate the Company's first clinical study for a follow-on biologic (FOB) product candidate. Insmed's INS-19, which is a recombinant form of human G-CSF, is a follow-on biologic of the FDA-approved product Neupogen(R), which had U.S. sales of approximately $0.9 billion in 2007.

Pre-clinical studies demonstrate that INS-19 and FDA-approved Neupogen(R) are comparable in both their pharmacological and toxicological profile. Detailed analytical characterisation also demonstrates that the products have a high degree of similarity. Data from these initial evaluations have been used, in part, to support the Phase I study, which will be initiated immediately. The Phase I study will be conducted in the UK and will compare the safety and establish the bioequivalence of INS-19 to Neupogen(R). Results from the trial are expected in the second half of 2008, and are planned to be used as part of a submission to the FDA to establish a protocol with the agency for a Phase III trial in the U.S.

"By utilizing Insmed's unique protein drug development capabilities and technical expertise, the Company has been able to advance a follow-on biologic product candidate from project initiation to human testing in less than one year, a significant achievement," said Geoffrey Allan, CEO of Insmed. "We intend to utilize the data generated from the Phase I trial, in combination with the positive preclinical results previously garnered, as the basis for discussions with the FDA in an effort to establish a Phase III development path for INS-19."

The initiation of this follow-on biologic trial is the first of two planned for 2008 as part of Insme
'/>"/>

SOURCE Insmed Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Insmed Launches National Awareness Campaign Surrounding Follow-On Biologics
2. Insmed Provides Update on IPLEX(TM) Expanded Access Program in Italy for the Treatment of Amyotrophic Lateral Sclerosis
3. Insmed Receives FDA Orphan Drug Designation for IPLEX(TM) in the Treatment of Myotonic Muscular Dystrophy
4. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
5. Texas Heart(R) Institute at St. Lukes Episcopal Hospital Initiates First Clinical Trial in the World to Treat a Heart Attack Patient with a Special Stem Cell Type
6. Kosan Initiates Phase 2 Trial of Epothilone KOS-1584 in Non-Small Cell Lung Cancer
7. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
8. Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
9. Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging
10. Metabolex Initiates Phase 1 Trial of MBX-2982
11. Phosphagenics Initiates its Phase 2 Clinical Trial in Type 1 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... , Sept. 23, 2014  Hill-Rom (NYSE: ... Providence Health ( Renton, WA ), the ... expands the companies, existing relationship as Hill-Rom now becomes ... Bariatric capital bed frame and surface products. ... systems in the U.S.  It operates 34 hospitals, 475 ...
(Date:9/23/2014)... Sept. 23, 2014  MEDIMETRIKS PHARMACEUTICALS today announced ... Resnick have been elected to Medimetriks, Board ... Mr. Lary, who will serve on Medimetriks, Audit ... experience to the Company.  Mr. Lary is currently ... a leading institutional investment firm.  Mr. Lary is ...
(Date:9/23/2014)... Sept. 23, 2014   COTA, Inc. today ... $7 million Series A funding round led by Horizon ... is the first big data platform designed by practicing ... analysis for cancer care in support of healthcare,s new ... to expand development of the COTA platform, hire biostatisticians, ...
Breaking Medicine Technology:Hill-Rom Announces Seven-Year, Sole-Source Contract with Providence Health 2Medimetriks Pharmaceuticals, Inc. Welcomes Independent Directors Andrew Lary and William Resnick to its Board of Directors 2COTA Closes $3.7M of Planned $7M Series A Funding Round to Transform Cancer Outcomes and Reimbursement 2COTA Closes $3.7M of Planned $7M Series A Funding Round to Transform Cancer Outcomes and Reimbursement 3COTA Closes $3.7M of Planned $7M Series A Funding Round to Transform Cancer Outcomes and Reimbursement 4
... MARINO, Calif. March 25, 2011 VG Energy, ... VRAL ), announced today that it ... to verify lab results on a large scale for the development ... VG Energy has developed proprietary technology, with results ...
... Ltd. (Nasdaq: SVA ), a leading provider ... Weidong Yin, President and CEO, and Ms. Helen Yang, ... UBS Greater China Healthcare Corporate Day.  The conference will ... March 28th to March 29.  The Sinovac team will ...
Cached Medicine Technology:VG Energy Contracts BioProcess Algae To Verify "Lipid Trigger" Results For Commercial Biofuels Production 2VG Energy Contracts BioProcess Algae To Verify "Lipid Trigger" Results For Commercial Biofuels Production 3VG Energy Contracts BioProcess Algae To Verify "Lipid Trigger" Results For Commercial Biofuels Production 4Sinovac Participates in UBS Greater China Healthcare Corporate Day 2
(Date:9/23/2014)... (PRWEB) September 23, 2014 Mel Frank, ... about cultivating, growing and harvesting marijuana. He is perhaps ... the field and he’ll be leading a special elective ... am to 5:00 pm at Oaksterdam University ... law, botany and nomenclature, harvesting and manicuring, and identifying ...
(Date:9/23/2014)... that FDG-PET technology is less accurate in diagnosing ... infections like histoplasmosis or tuberculosis are common. ... lead to unnecessary tests and surgeries for patients, ... Histoplasmosis and other fungal diseases are linked to ... and are found in soils. , The study ...
(Date:9/23/2014)... San Diego, CA (PRWEB) September 23, 2014 ... website daily regarding all the latest information from the ... announced on September 5, that its Private Label Jalapeno ... glass and small stones. Publix Jalapeno Bagels ... in the bakery department. , Taking into consideration ...
(Date:9/23/2014)... 2014 (HealthDay News) -- A test used to diagnose lung ... certain lung infections are more common, a new analysis says. ... through the use of what,s known as functional imaging. For ... is used, according to the study authors. Cancerous tumors ... parts of the lungs that don,t have cancer, according to ...
(Date:9/23/2014)... 23, 2014 Grinnell Mutual seeks ... projects in the Midwest. Working Together Making It ... non-profit organizations with projects positively impacting their communities. ... marketplace make their communities a better places,” said ... Community Relations Barb Baker. “Their leadership—as coaches, as ...
Breaking Medicine News(10 mins):Health News:Special Elective Course Added to Oaksterdam University Schedule; Unique Opportunity to Learn From the “Godfather of Cannabis” Mel Frank on September 27, 2014 2Health News:Study questions accuracy of lung cancer screens in some geographic regions 2Health News:Publix Private Label Jalapeno Bagels Recalled: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Lung Infections May Hamper Ability to Detect Lung Cancer 2Health News:Grinnell Mutual Invites Submissions for Innovative, Collaborative Local Projects in Its Second Annual Working Together Making It Better Promotion 2
... death rates, longer hospital stays and greater costs , , ... (GI) bleeding admitted to hospitals on weekends are more ... to two studies that analyzed U.S. patient data. ... upper gastrointestinal hemorrhage (NVUGIH) admitted on weekends were 36 ...
... of Your Mental Health Talk Radio www.blogtalkradio.com/yourmentalhealth when ... Men Are From Mars, Women Are From Venus ... new book When Mars and Venus Collide: Improving Relationships ... on Thursday, March 5th at 8 PM EST/5 PM ...
... Hit Unprecedented Lows; Approximately Half of Hospitals UnprofitableANN ... margin of U.S. hospitals has fallen to zero ... hospital finances published today. Driven largely by ... apparent in all types of hospitals - small, ...
... than 52,000 patients from eight countries has shown that ... improvements and greater patient satisfaction. , The findings, ... International Journal of Clinical Practice , show that 53 ... less than seven per cent, the target set by ...
... users with Zix CorporationDALLAS, March 2 Zix Corporation ... Blue Shield of Massachusetts (BCBSMA) today announced a contract ... Zix Corporation and Blue Cross Blue Shield of Massachusetts ... entering its sixth year. Under the contract terms, ...
... Edwin Ishoo , MD, an Otolaryngologist and facial ... the use of both minimally invasive and non-invasive techniques ... procedures implemented by Dr. Ishoo are also designed to ... activities as soon as possible."We are committed to using ...
Cached Medicine News:Health News:Weekend Admission May Be Riskier for GI Bleeding 2Health News:John Gray Will Discuss His New Book Why Mars and Venus Collide 2Health News:Thomson Reuters Study Tracks Impact of Recession on Hospitals 2Health News:Thomson Reuters Study Tracks Impact of Recession on Hospitals 3Health News:Insulin drug study shows significant improvements in more than 52,000 diabetic patients 2Health News:Insulin drug study shows significant improvements in more than 52,000 diabetic patients 3Health News:Zix Corporation and Blue Cross Blue Shield of Massachusetts Expand the Industry's Largest e-Prescribing Program 2Health News:Edwin Ishoo MD Providing Non-Invasive Cosmetic Procedures, Minimizing Recovery Time 2
... 210, Carl Zeiss has created a surgical microscope ... for ophthalmic surgery. Its wide range of uses ... and it offers new functions to improve depth ... integrated assistant's microscope the OPMI VISU 210 is ...
Blood grouping tubes are available in two formulations, ACD-A, ACD-B or with a CPDA solution. Blood grouping tubes are for blood grouping determinations and also for cell preservation....
MONOJECT Brown Stopper...
BD Vacutainer® PST™ Tubes contain spray-coated lithium heparin and a gel for plasma separation. They are used for plasma determinations in chemistry....
Medicine Products: